Floatz logo

Azacitidine

Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation

Explore 15 assets in Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation →
Floatz Rating
BB69/100
Confidence
Indicative
v0.2
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07028073CT.gov
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
—Recruiting———
NCT01869114CT.gov
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
—Completed———
NCT01839240CT.gov
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
—Completed———
NCT01083706CT.gov
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
—Completed———
NCT00895934CT.gov
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
—Completed———
NCT00658814CT.gov
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation

AssetSponsorPhaseRating
Azacitidine (this asset)The First Affiliated Hospital of Soochow UniversityP2BB · 69
DaunomycinNational Cancer Institute (NCI)P3BBB
EtoposideAlice MimsP3BBB
CytarabineThe First Affiliated Hospital of Soochow UniversityP3BBB
IdarubicinThe First Affiliated Hospital of Soochow UniversityP2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)P2BBB
MitoxantroneBGI, ChinaP2BBB
CyclophosphamideBGI, ChinaP3BBB
FludarabineRutgers, The State University of New JerseyP3BB

+42 more in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Azacitidine in Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/azacitidine-acute-myeloid-leukemia-with-t821q22q22-translocation

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →